AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11732951
Drug: Nebulized isotonic
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized isotonic sodium chloride solution, 1 mL (Control)
Trial: 9209775
Drug: Sumatriptan suppository
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan suppository 12.5 mg
Trial: 9209775
Drug: Sumatriptan suppository
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan suppository 25 mg
Trial: 9209775
Drug: Sumatriptan suppository
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan suppository 50 mg
Trial: 9209775
Drug: Sumatriptan suppository
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan suppository 100 mg
Trial: 9209775
Drug: Sumatriptan suppository
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumatriptan suppository 50 mg (twice a day for 11 doses)
Trial: 9209775
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository (twice a day for 11 doses)
Trial: 8480688
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg Zn (as gluconate)/d for 60 days
Trial: 3304688
Drug: VAP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAP plus 2 years of oral maintenance chemotherapy
Trial: 22019520
Drug: TG4010 plus
RxNorm normalized name: TG4010
DrugBank: TG4010 (DB06584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4010 plus chemotherapy
Trial: 26727163
Drug: TG4010 plus
RxNorm normalized name: TG4010
DrugBank: TG4010 (DB06584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4010 plus chemotherapy (TrPAL ≤ ULN)
Trial: 26727163
Drug: TG4010 plus
RxNorm normalized name: TG4010
DrugBank: TG4010 (DB06584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4010 plus chemotherapy (TrPAL > ULN)
Trial: 24598493
Drug: No root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No root canal preparation (Subgroup 2.3)
Trial: 23141853
Drug: Percutaneous intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous intervention plus optimal medical therapy (PCI)
Trial: 23141853
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (MED) alone
Trial: 11021737
Drug: Topotecan (2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (2.3 mg/m2 per day for 5 days every 21 days) with ranitidine (150 mg twice daily for 4 days before day 1 of one of the first two courses and 150 mg given 2 h before the first topotecan dose)
Trial: 6471773
Drug: No beta-Interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-Interferon treatment
Trial: 6471773
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (adriamycine, cyclophosphamide, vincristine, dacarbazine)
Trial: 30051507
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application for Cognitive Behavioral Therapy (CBT)
Trial: 26863155
Drug: trans‐resveratrol‐based supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trans‐resveratrol‐based supplement (Longevinex®)
Trial: 22933049
Drug: Epilepax® (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epilepax® (test formulation)
Trial: 15358571
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (CS) applied for 48 hours before prick-testing.
Trial: 15358571
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of methylprednisolone immediately after prick-testing.
Trial: 18495436
Drug: Ziprasidone IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone IM 2 mg
Trial: 8046805
Drug: Fixed-schedule therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-schedule therapy (standard course of chlordiazepoxide four times daily with additional medication as needed)
Trial: 3054280
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg before test meals
Trial: 30086709
Drug: 0.75 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 μg/kg DEX
Trial: 30086709
Drug: 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/kg DEX
Trial: 25399973
Drug: Paclitaxel/Carboplatin (Carboplatin:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel/Carboplatin (Carboplatin: AUC 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; Paclitaxel: 200 mg/m², 21-day cycle)
Trial: 10576189
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 50 microg every 4 hours as needed
Trial: 1662638
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg on day 1, 250 mg on days 2-5)
Trial: 1662638
Drug: Cephalexin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (500 mg b.i.d. for ten days)
Trial: 7046908
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg/m2 orally three times a week) with chemotherapy
Trial: 7046908
Drug: Reduced dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced dosage of levamisole (2.5 mg/kg or 100 mg/m2 three times a week, every other week) with chemotherapy
Trial: 21845387
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of dexamethasone (8 mg)
Trial: 21845387
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of dexamethasone (8 mg)
Trial: 16167288
Drug: Fixed-combination brimonidine
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID (n = 188)
Trial: 16167288
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (fixed-combination and concomitant)
Trial: 8679790
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg TRH just prior to ECT
Trial: 2066545
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg at bedtime and Placebo
Trial: 6606576
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (aorto-coronary bypass surgery)
Trial: 26280534
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (60 mg)
Trial: 17523910
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg/day for 4 weeks (group C)
Trial: 17523910
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg/day for 4 weeks (group D)
Trial: 6342353
Drug: Prazosin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 20 mg/day
Trial: 31755292
Drug: collagen 4
RxNorm normalized name: collagen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: collagen 4 ml
Trial: 31755292
Drug: trimecaine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimecaine 1% 4 ml
Trial: 25457123
Drug: Problem-Solving Treatment
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-Solving Treatment (PST) - six 1-hour sessions
Trial: 23284689
Drug: SRT2104 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 (0.5 or 2.0 g)
Trial: 15707388
Drug: CC carriers
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC carriers
Trial: 12072722
Drug: Desonide 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desonide 0.25% ophthalmic solution
Trial: 9491286
Drug: Weekly doses
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly doses of intravenous iron dextran for 6 weeks
Trial: 27222511
Drug: LDL cholesterol
RxNorm normalized name: LDL cholesterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL cholesterol levels >2.5 mmol/L
Trial: 14632771
Drug: Intermediate-dose cytosine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose cytosine arabinoside (1 g/m2/2 h) b.i.d. for 4 days with idarubicin (CCI)
Trial: 1679065
Drug: Oxatomide 1
RxNorm normalized name: chlophedianol hydrochloride 15 MG / guaiacol ethylglycolate 10 MG / oxatomide 10 MG per 5 ML Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide 1 mg/kg/day
Trial: 24831445
Drug: VAS203 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAS203 (20 mg/kg for 48 hours)
Trial: 24831445
Drug: VAS203 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAS203 (30 mg/kg for 72 hours)
Trial: 8151105
Drug: Recombinant alpha
RxNorm normalized name: Recombinant alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha interferon 2b (rIFN‐alpha 2b) 15 million units, 3 times a week for 4 months plus 150 mg of levamisole for the first 6 weeks
Trial: 3731535
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol content beer (64 ml/week)
Trial: 3731535
Drug: Normal drinking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal drinking habits (452 ml ethanol/week)
Trial: 23164997
Drug: PGA sheet
RxNorm normalized name: PGA
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGA sheet and fibrin glue spray
Trial: 21252701
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Telmisartan 80 mg and Nifedipine GITS 20 mg
Trial: 7515730
Drug: CEMB regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEMB regimen (cisplatin 50 mg/m2 day 1, vindesin 3 mg/m2 day 1, mitomycin 6 mg/m2 day 2, bleomycin 15 mg/day, day 1 + 2 by continuous infusion)
Trial: 31082494
Drug: Afatinib in
RxNorm normalized name: Product containing afatinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib in combination with postoperative radiation therapy (PORT)
Trial: 31082494
Drug: Afatinib in
RxNorm normalized name: Product containing afatinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib in combination with PORT and weekly docetaxel
Trial: 31082494
Drug: Afatinib in
RxNorm normalized name: Product containing afatinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib in combination with PORT
Trial: 30650497
Drug: Modified Dachengqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Dachengqi Decoction (500 mL) once a day for 2 weeks
Trial: 9795924
Drug: CIFN 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIFN 9 micrograms, three times weekly for 24 weeks
Trial: 9795924
Drug: CIFN 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIFN 15 micrograms, three times weekly for 48 weeks
Trial: 9795924
Drug: IFN‐alpha‐2b 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha‐2b 3 MU administered 3 times per week for 6 to 12 months
Trial: 22030199
Drug: Lidocaine jet
RxNorm normalized name: lidocaine Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine jet injection (0.2 mL of lidocaine 2%)
Trial: 19606510
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (waiting list, no treatment)
Trial: 9504953
Drug: Vitamin D-fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D-fortified liquid milk (500 ml per day)
Trial: 1673134
Drug: Metoprolol, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol, 100 mg twice daily
Trial: 30899086
Drug: Molecular apocrine
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular apocrine (MA) subtype patients receiving neoadjuvant chemotherapy
Trial: 19848196
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SFI), 60 mL once a day for 10 days each month over a treatment course of 6 months.
Trial: 19848196
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (Control group).
Trial: 3704898
Drug: Subcutaneous drains
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous drains
Trial: 11968069
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release formulations of metoprolol (100 mg) with varying release rates (slow, moderate, fast)
Trial: 11968069
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of metoprolol (50 mg)
Trial: 11968069
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release formulations of metoprolol (100 mg) with fast input
Trial: 10886120
Drug: GR205171 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR205171 25 mg i.v.
Trial: 28297698
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 3 months)
Trial: 20156926
Drug: TPA023B (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA023B (1.5 mg)
Trial: 20156926
Drug: TPA023B (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA023B (10 mg/kg)
Trial: 30595329
Drug: Carvedilol 6.25
RxNorm normalized name: carvedilol 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 6.25 mg/day
Trial: 29415258
Drug: Brexpiprazole 1-4
RxNorm normalized name: brexpiprazole 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole 1-4 mg/d
Trial: 27530473
Drug: Anthocyanin-rich purple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanin-rich purple sweet potato beverage (PSP), 177 mg anthocyanins per 125-ml bottle, 3 bottles per day for 8 weeks
Trial: 25069476
Drug: Genetic variants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic variants associated with drug reactions (rs1799929 and rs1495741 in NAT2)
Trial: 327854
Drug: Droperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (5 mg)
Trial: 31501069
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline solution)
Trial: 21917777
Drug: Responsive cortical
RxNorm normalized name: Corticool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responsive cortical stimulation (treatment)
Trial: 11378006
Drug: Metoprolol (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50, 100, and 200 mg)
Trial: 11378006
Drug: Carvedilol (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25, 50, and 100 mg)
Trial: 7954233
Drug: Temporary hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary hepatic artery occlusion followed by intraportal infusion of 5‐fluorouracil (5‐FU) and oral allopurinol
Trial: 7954233
Drug: No regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No regional or systemic treatment
Trial: 31724966
Drug: placebo 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1.5 ml, pen-injector for subcutaneous injection
Trial: 18679148
Drug: Noninvasive ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive ventilation (NIV) plus standard therapy
Trial: 15381054
Drug: Aggrenox (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggrenox (2 pills/daily)
Trial: 15381054
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg plus matching placebo/daily)
Trial: 11183453
Drug: Clindamycin ovule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin ovule (3-day treatment)
Trial: 30367673
Drug: Metronidazole vaginal
RxNorm normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole vaginal gel
Trial: 8752295
Drug: Bovine rotavirus
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine rotavirus vaccines
Trial: 8752295
Drug: RRV-based vaccines
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV-based vaccines
Trial: 8752295
Drug: All vaccines
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccines with demonstrable immunogenicity
Trial: 1371211
Drug: Corticosteroids plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids plus intravenous cyclophosphamide
Trial: 29908826
Drug: Intramyocardial CD34+
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial CD34+ cell therapy (5 × 10^4 to 5 × 10^5 cells/kg)
Trial: 15200199
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron (4mg)
Trial: 9916605
Drug: Valsartan 10
RxNorm normalized name: valsartan 103 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 10 mg
Trial: 9220209
Drug: Valsartan 20
RxNorm normalized name: valsartan 20 MG in 5 mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 20 mg
Trial: 20236700
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg
Trial: 3195836
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (20 mg 3 times a day)
Trial: 9004191
Drug: Extended-release experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release experimental formulations (80 mg)
Trial: 9004191
Drug: Inderal immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderal immediate-release dosage form (2 x 40 mg)
Trial: 1359318
Drug: Mefloquine 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 1250 mg in divided doses
Trial: 18230968
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Trial: 2129319
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg PM
Trial: 2129319
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg bid
Trial: 2129319
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg AM
Trial: 19242406
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg memantine
Trial: 8628597
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg/d
Trial: 29650688
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy (doxorubicin, doxorubicin + ifosfamide, epirubicin, trabectedin, ifosfamide)
Trial: 24852464
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil cream applied every day for 4 weeks
Trial: 24852464
Drug: 4 weekly
RxNorm normalized name: TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weekly peels of 5% 5-fluorouracil
Trial: 22573238
Drug: Increases in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increases in ESA doses (>0 U)
Trial: 22573238
Drug: Larger increases
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger increases in hemoglobin (>1.0 g/dL/month)
Trial: 15178637
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg daily for 4 weeks
Trial: 10097818
Drug: Short peptides
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short peptides with Tpo activity; details on dosage and duration not available.
Trial: 3512670
Drug: Chlorthalidone 12.5
RxNorm normalized name: chlorthalidone 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 12.5 mg